Compounds > piracetam
Page last updated: 2024-11-02

piracetam and MPTP Neurotoxicity Syndrome

piracetam has been researched along with MPTP Neurotoxicity Syndrome in 2 studies

Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.

Research Excerpts

ExcerptRelevanceReference
"L-3,4 dihydroxyphenylalanine (levodopa)-induced dyskinesia in Parkinson's disease patients is characterized by a mixture of chorea and dystonia."3.72Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. ( Bezard, E; Brotchie, JM; Crossman, AR; Grimée, R; Hill, MP; Klitgaard, H; Michel, A, 2004)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bezard, E2
Hill, MP2
Crossman, AR2
Brotchie, JM2
Michel, A2
Grimée, R2
Klitgaard, H2
Ravenscroft, P1

Other Studies

2 other studies available for piracetam and MPTP Neurotoxicity Syndrome

ArticleYear
Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
    European journal of pharmacology, 2004, Feb-06, Volume: 485, Issue:1-3

    Topics: Animals; Chorea; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induc

2004
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2004, Volume: 310, Issue:1

    Topics: Amantadine; Animals; Anticonvulsants; Antiparkinson Agents; Callithrix; Disease Models, Animal; Drug

2004